| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Denali Capital Acquisition Corp. | 10%+ Owner | Class B Ordinary Shares | 1,432,500 | 30 Aug 2024 | Indirect | ||
| Estrella Immunopharma, Inc. | Chief Financial Officer | Nonstatutory Share Option | 509,203 | 30 Oct 2024 | Direct | ||
| Estrella Immunopharma, Inc. | Chief Financial Officer | Incentive Share Option | 490,796 | 30 Oct 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ESLA | Estrella Immunopharma, Inc. | 30 Oct 2024 | 2 | $0 | 4 | Chief Financial Officer | 14 Feb 2025, 16:30 |
| DNQAF | Denali Capital Acquisition Corp. | 30 Aug 2024 | 1 | $0 | 4 | 10%+ Owner | 16 Sep 2024, 10:01 |
| ESLA | Estrella Immunopharma, Inc. | 29 Sep 2023 | 0 | $0 | 3 | Chief Financial Officer | 10 Oct 2023, 16:18 |
| DNQAF | Denali Capital Acquisition Corp. | 21 May 2022 | 1 | $0 | 4 | 10%+ Owner | 24 May 2022, 16:20 |
| DNQAF | Denali Capital Acquisition Corp. | 11 Apr 2022 | 1 | +$5,100,000 | 4 | 10%+ Owner | 13 Apr 2022, 16:51 |
| DNQAF | Denali Capital Acquisition Corp. | 06 Apr 2022 | 0 | $0 | 3 | 10%+ Owner | 06 Apr 2022, 20:45 |